C URRENT OPINION Regulation of lipid metabolism by microRNAs
Rothwelle Tate, Dino Rotondo, and Jillian Davidson microRNAs (miRNAs) are a class of small noncoding RNAs, typically 22 nucleotides in length, which post-transcriptionally regulate gene expression. Mature miRNAs bind complementary sequences in the 3 0 untranslated region of target mRNAs and repress protein expression via a number of mechanisms including mRNA destabilization and/or inhibition of translation [1] . So far, almost 36 000 mature miRNAs from 223 species have been classified with 2588 of them human (miRBase, Release 21) [2,3 & ]. As a single miRNA is able to target hundreds of transcripts in humans, they are likely to influence regulation of all cellular events [4, 5] and their dysregulation has been correlated with disease pathogenesis [6] . In addition to acting endogenously, miRNAs can be released from cells where they may be involved in cell-cell communication and extracellular regulatory mechanisms and have been detected in many body fluids [7, 8] . These extracellular, circulating miRNAs may be noninvasive biomarkers of disease and targets for therapeutic intervention [9, 10] .
Individual miRNAs have been found to regulate specific genes involved in lipid metabolism. He et al. [11 && ] utilized target prediction to identify the possible regulation of lipoprotein lipase (LPL) by miR-590. They used synthetic miR-590 miRNA with human THP-1 macrophages to demonstrate for the first time that miR-590 may be involved in atherosclerosis by negatively regulating lipid accumulation, lipid-laden foam cell formation, and proinflammatory cytokine (including tumour necrosis factor-a and interleukin-1b) production via downregulation of LPL expression. In a related manner, it has been shown by Vickers et al. [12 && ] that a single miRNA, miR-223, plays a critical role coordinating lipid metabolism by post-transcriptionally regulating multiple genes which control uptake, efflux, and biosynthesis of cholesterol. miR-223 appears to achieve this through the downregulation of the expression of both Hmgcs1 (3-hydroxy-3methylglutaryl-CoA synthase 1) and Scarb1 (scavenger receptor class B member 1), inhibiting cholesterol synthesis. miR-223 was also found to have an indirect effect on ATP-binding cassette transporter 1 (ABCA1) activity via a repression of Sp3 transcription factor. The expression of miR-223 was itself found to be linked with cholesterol levels, with decreased miR-223 transcription during cholesterol depletion, providing a case for its potential use in diagnostics as a circulating biomarker for altered cholesterol homeostasis. Cholesterol efflux, which has been regarded as an important cholesterol regulatory mechanism, has been shown in other studies to be controlled by miRNAs. miR-33a and miR-33b located within the intron of the sterol regulatory element-binding protein genes SREBF2 and SREBF1, coding for major transcription factors controlling cholesterol and fatty acid metabolism. These are cotranscribed in cholesterol-depleted conditions [13] . miR-33a is expressed in human macrophages and hepatocytes and regulates cholesterol efflux and HDL synthesis via gene repression of cholesterol transporter proteins including ABCA1 [14] . ABCA1, which contains putative binding sites for miR-33a and miR-33b in its 3 0 untranslated region, mediates efflux of free cholesterol which then forms HDL and is of particular importance in lipid-laden macrophages (foam cells) for removal of excess cholesterol out of the cell by reverse cholesterol transport. Regulation of ABCA1-targeting miRNAs holds great therapeutic potential in the treatment of atherosclerosis, via cholesterol homeostasis as small changes in their expression influences ABCA1 activity, in turn leading to large changes in HDL-cholesterol levels [15, 16] Although our understanding of the roles of miRNA regulation in lipid metabolism is rapidly growing, the practical use of this knowledge in the clinical application of treatments such as anti-miRs and miRNA-mimics for lipid disorders will experience the many challenges RNAi-based therapeutics face, including their need for targeted
